Iradimed (IRMD) Cash from Operations Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | Iradimed | 1.17 Bn | 1.11 Bn | 16.81 Mn | 21.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.29% |
| Dec 31, 2025 | 24.91% |
| Sep 30, 2025 | 21.05% |
| Jun 30, 2025 | 67.81% |
| Mar 31, 2025 | 44.38% |
| Dec 31, 2024 | 21.16% |
| Sep 30, 2024 | 39.22% |
| Jun 30, 2024 | 22.96% |
| Mar 31, 2024 | 60.28% |
| Dec 31, 2023 | 16.16% |
| Sep 30, 2023 | 1.44% |
| Jun 30, 2023 | 64.41% |
| Mar 31, 2023 | 57.17% |
| Dec 31, 2022 | -8.36% |
| Sep 30, 2022 | 7.86% |
| Jun 30, 2022 | -12.90% |
| Mar 31, 2022 | 28.95% |
| Dec 31, 2021 | -1.69% |
| Sep 30, 2021 | 66.80% |
| Jun 30, 2021 | 32.88% |
| Mar 31, 2021 | -15.87% |
| Dec 31, 2020 | 21.23% |
| Sep 30, 2020 | -11.24% |
| Jun 30, 2020 | 39.45% |
| Mar 31, 2020 | 103.93% |
| Dec 31, 2019 | 21.10% |
| Sep 30, 2019 | -2.83% |
| Jun 30, 2019 | 23.09% |
| Mar 31, 2019 | -35.09% |
| Dec 31, 2018 | 11.34% |
| Sep 30, 2018 | -32.27% |
| Jun 30, 2018 | -3.30% |
| Mar 31, 2018 | 14.46% |
| Dec 31, 2017 | 52.61% |
| Sep 30, 2017 | 15.46% |
| Jun 30, 2017 | -45.34% |
| Mar 31, 2017 | -33.88% |
| Dec 31, 2016 | 42.55% |
| Sep 30, 2016 | 164.47% |